Teleflex Incorporated
TFXHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframePart of the healthcare sector, Teleflex Incorporated (TFX) is listed under Medical Instruments & Supplies. Valued at $5.86B, TFX is a mid-cap name in its sector. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand.
Market Cap
$5.86B
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
12.63
EPS (TTM)
$-0.53
EPS (Fwd)
$10.95
ROE
-0.7%
ROA
1.8%
Cash
$323.9M
Total Debt
$2.94B
Free CF
$179.5M
52W Change
6.2%
Annual Financials
Cash vs Debt
Where TFX stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, TFX finished 12.29% above its 150-day moving average ($123.55) and 14.26% above its 200-day moving average ($121.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TFX overbought or oversold?
At the August 27, 2026 close, TFX's RSI(14) was 50.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Teleflex Incorporated carries $2.94B in total debt against $323.9M in cash reserves — debt is roughly 9.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $179.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -0.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has pulled back from $2.79B (2022) to $1.99B (2025), a 29% decline worth watching.
Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. No single metric tells the full story. Reviewing TFX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.